organophosphonates has been researched along with 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline in 3 studies
Studies (organophosphonates) | Trials (organophosphonates) | Recent Studies (post-2010) (organophosphonates) | Studies (2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline) | Trials (2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline) | Recent Studies (post-2010) (2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline) |
---|---|---|---|---|---|
9,968 | 880 | 3,596 | 1,216 | 0 | 229 |
Protein | Taxonomy | organophosphonates (IC50) | 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline (IC50) |
---|---|---|---|
Glutamate receptor 1 | Rattus norvegicus (Norway rat) | 0.5781 | |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | 0.5781 | |
Glutamate receptor 3 | Rattus norvegicus (Norway rat) | 0.5781 | |
Glutamate receptor 4 | Rattus norvegicus (Norway rat) | 0.5781 | |
Glutamate receptor ionotropic, kainate 1 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, kainate 2 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor 1 | Homo sapiens (human) | 6 | |
Glutamate receptor 2 | Homo sapiens (human) | 2.5 | |
Glutamate receptor 3 | Homo sapiens (human) | 1.9 | |
Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor 4 | Homo sapiens (human) | 1.1 | |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, kainate 4 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, kainate 5 | Rattus norvegicus (Norway rat) | 2.909 | |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.2 | |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.2 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cordi, AA; Desos, P; Lepagnol, JM; Lestage, P; Morain, P | 1 |
Groom, A; Smith, T; Turski, L; Zhu, B | 1 |
Abe, K; Chou, DY; Janssen, MJ; Partridge, JG; Vicini, S; Zukowska, Z | 1 |
3 other study(ies) available for organophosphonates and 2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline
Article | Year |
---|---|
Structure-activity relationships in a series of 2(1H)-quinolones bearing different acidic function in the 3-position: 6,7-dichloro-2(1H)-oxoquinoline-3-phosphonic acid, a new potent and selective AMPA/kainate antagonist with neuroprotective properties.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Brain; Brain Ischemia; Electrophysiology; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Gerbillinae; Kainic Acid; Mice; Molecular Structure; N-Methylaspartate; Neuroprotective Agents; Organophosphonates; Quinolones; Quinoxalines; Rats; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Xenopus | 1996 |
Autoimmune encephalomyelitis ameliorated by AMPA antagonists.
Topics: Animals; Brain Stem; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Excitatory Amino Acid Antagonists; Guinea Pigs; Motor Neurons; Multiple Sclerosis; Muscle Tonus; Myelin Basic Protein; Neurons; Organophosphonates; Quinoxalines; Rats; Rats, Inbred Lew; Receptors, AMPA; Receptors, Kainic Acid; Recurrence; Spinal Cord; T-Lymphocytes | 2000 |
Excitatory and inhibitory synapses in neuropeptide Y-expressing striatal interneurons.
Topics: Animals; Bicuculline; Biophysical Phenomena; Biophysics; Choline O-Acetyltransferase; Corpus Striatum; Electric Stimulation; Excitatory Amino Acid Antagonists; GABA Antagonists; Green Fluorescent Proteins; Interneurons; Mice; Mice, Transgenic; Neural Inhibition; Neuropeptide Y; Organophosphonates; Parvalbumins; Patch-Clamp Techniques; Piperazines; Quinoxalines; Sodium Channel Blockers; Synapses; Synaptic Potentials; Tetrodotoxin | 2009 |